TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of an AcrySof IQ PanOptix Toric Intraocular Lens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Eligible to be implanted with AcrySof IQ PanOptix Toric Intraocular Lens Model TFNT20 in at least one eye.~* Potential postoperative Best Corrected Distance Visual Acuity (BCDVA) of 0.5 decimal or better.~* Other protocol-specified inclusion criteria may apply.~Key Exclusion Criteria:~* Irregular corneal astigmatism.~* History of anterior segment, posterior segment, or optic nerve pathology.~* History of previous intraocular or corneal (refractive or trauma related) surgery.~* Any other planned ocular surgical procedures including but not limited to limbal relaxing incision (LRI)/Astigmatic Keratotomy and laser assisted in situ keratomileusis (LASIK).~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PanOptix Toric Trifocal IOL (Type: EXPERIMENTAL): ACRYSOF IQ PanOptix Toric Trifocal IOL Model TFNT20 implanted in the capsular bag in the posterior chamber following cataract surgery. At least one eye will be implanted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients with severe congenital haemophilia A (FVIII activity level below 1%)~* Weight above or equal to 10 kg - Documented history of 150 exposure days (ED) to FVIII products for patients aged 6-11 years and above 50 ED to FVIII products for patients aged 0-5 years~Exclusion Criteria:~- Any history of FVIII inhibitors

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- N8-GP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* Disease progression following androgen ablation therapy (hormonal or surgical) by either:~  * Increase in the product of bidimensional diameters of 1 or more radiographically documented sites of measurable disease OR~ * Two consecutive increases in PSA documented over a previous reference value~    * First increase in PSA should occur a minimum of 1 week from the reference value and be confirmed~   * First PSA value is less than the previous value, then patient is eligible provided next PSA is greater than the second PSA~* Testosterone levels documented in the castrate range (i.e., less than 30 ng/mL)~PATIENT CHARACTERISTICS:~Age:~* 18 to 85~Performance status:~* CALGB 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Bilirubin normal~* SGOT no greater than 2.5 times upper limit of normal (ULN) if alkaline phosphatase normal OR~* Alkaline phosphatase no greater than 4 times ULN if SGOT normal OR~* SGOT no greater than 1.5 times ULN and alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No myocardial infarction within past year~* No significant change in anginal pattern within past 6 months~* No New York Heart Association class II-IV heart disease~* No deep venous thrombosis within past year~Other:~* No significant peripheral neuropathy~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior chemotherapy allowed except taxanes or platinum derivatives~Endocrine therapy:~* See Disease Characteristics~* At least 4 weeks since prior antiandrogens~Radiotherapy:~* At least 4 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is ambulatory male or female~* Patient's body mass index score is \> 20 and \< 40 kg/m\^2 at the Screening Visit~* Women of childbearing potential must have a negative pregnancy test at the time of screening and check-in and must agree to use protocol-specified contraception throughout the duration of the study~* Patient's health is stable with no clinically significant findings on physical examination~* Patient has type 2 (ie, adult onset) diabetes mellitus diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit, is on a stable glycemic control medication, and protocol specified hemoglobin (Hb)A1c values at the Screening Visit~* Patient has hypertension diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit, and blood pressure (BP) within the protocol's acceptable range~* Patients must be on a stable regimen for hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), stable for 28 days~* Other inclusion criteria per protocol~Exclusion Criteria:~* Patient has a clinically significant active or unstable medical condition that, in the opinion of the Investigator, would preclude trial participation~* Patient is on medication(s) that, when co-administered with a sGC stimulator, could increase the risk of hypotension~* Patient has evidence of severe or active end-organ damage~* Patient is an active smoker or has used any nicotine-containing products (cigarettes, e-cigarettes, vape pens, cigars, chewing tobacco, gum, patches) during the 6 months before Check-in. Use of nicotine is excluded during the study until after the End of Trial Visit.~* Other exclusion criteria per protocol

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IW-1973 QD/QD (Type: EXPERIMENTAL): On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
- IW-1973 BID (Twice Daily)/QD (Type: EXPERIMENTAL): On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
- Placebo (Type: PLACEBO_COMPARATOR): On Days 1-14: Placebo taken in AM and in PM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of uncomplicated PID based on the absence of pelvic or tubo-ovarian abscess at pelvic ultrasound and/or laparoscopic examination.~Exclusion Criteria:~* Subjects with impaired liver and renal function; known hypersensitivity to study drugs, related compounds or any of the excipients.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin (Type: EXPERIMENTAL): Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
- Levofloxacin plus Metronidazole (Type: ACTIVE_COMPARATOR): Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Irritative voiding symptoms to include sensory urgency, frequency, urge incontinence, nocturia~* Postmenopausal women with a prior oophorectomy or 1 year from last menstrual period~* Women age 40-90~* Women with hysterectomy with preserved ovaries must be age 55 or greater or have a documented follicle-stimulating hormone (FSH)\>40 to ensure post-menopausal status~* Community dwelling~* Ambulatory~* Ability to participate in a 12 month study~Exclusion Criteria:~* Post-void residual volume\>150ml~* Glaucoma without ophthalmologist clearance~* Hormone replacement therapy in the past 6 months~* Current anticholinergic treatment~* Breast cancer~* Impaired mental status~* Undiagnosed vaginal bleeding in the past 12 months~* Endometrial thickness on pelvic ultrasound \>5mm~* History of thromboembolic event~* Gynecologic cancer~* Untreated urinary tract infection (would be eligible after treatment)~* Stage III pelvic organ prolapse or greater~* Recent diuretic medication changes (one month from change)~* Neurologic condition affecting bladder function (Multiple Sclerosis, Parkinsons, spinal cord injury, spina bifida)~* Congestive heart failure~* Prior pelvic irradiation~* Interstitial cystitis

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Extended Release Tolterodine LA (Type: ACTIVE_COMPARATOR): An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
- Intra Vaginal Estradiol Cream (Type: ACTIVE_COMPARATOR): For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Poor glycemic control (HbA1c ≥7.5%)~* Stable basal bolus insulin regimen for almost a year, eventually associated with metformin.~Exclusion Criteria:~* Type 1 diabetes or secondary diabetes;~* Previous treatment for the last three months with GLP-1RA or DPP-4 inhibitors;~* Hypersensitivity towards active substances or other ingredients of the drugs used in the study~* Participation in other trial with experimental drugs within 30 days~* Diseases that represent contraindication to GLP-1RA use (pancreatitis, gallstones)~* Pregnancy or planned pregnancy within the time of the study~* Serum creatinine \> 1,3 mg/dL in women and \>1,4 mg/dL in men~* eGFR \< 30 mL/min~* Previous cancer or antineoplastic therapy for five years before randomization~* Current therapy with glucocorticoid (oral, topic or sistemic administration) or with antypsichotic drugs~* Previous ketoacidosis~* Any clinical, psychologic or psychiatric condition that is incompatible with the study according to the investigator

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FR insulin/GLP-1RA (Type: ACTIVE_COMPARATOR): Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
- Insulin/SGLT-2i (Type: ACTIVE_COMPARATOR): Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
- Basal Bolus (Type: ACTIVE_COMPARATOR): Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, greater than or equal to (\>=) 12 years of age.~* Severe hemophilia A or B with inhibitors.~  * (Severity confirmed by a central laboratory where coagulation factor VIII (FVIII) level was less than (\<)1% or factor IX (FIX) level was less than or equal to \[\<=\]2% at Screening; Inhibitors defined as inhibitor titer of \>=0.6 Bethesda units per milliliter \[BU/mL\] or as evidenced by medical records).~* A minimum of 6 bleeding episodes requiring BPA treatment within the last 6 months prior to screening.~* Willing and able to comply with the study requirements and to provide written informed consent and assent.~Exclusion Criteria:~* Known co-existing bleeding disorders other than hemophilia A or B.~* Antithrombin (AT) activity \<60% at Screening.~* Co-existing thrombophilic disorder.~* Clinically significant liver disease.~* Active hepatitis C virus infection.~* HIV positive with a cluster of differentiation-4 count of \<200 cells/microliter.~* History of arterial or venous thromboembolism.~* Inadequate renal function.~* History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine.~* History of intolerance to SC injection(s).~* Any other conditions or comorbidities that would make the participant unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgement.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bypassing Agents (BPA) On-demand (Type: ACTIVE_COMPARATOR): Participants received On-demand BPAs (use of these agents, as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion from Day 1 for treatment of breakthrough bleeding episodes, up to a total of 9 months.
- Fitusiran 80 mg Prophylaxis (Type: EXPERIMENTAL): Participants received Fitusiran 80 mg subcutaneously (SC) as prophylaxis once monthly from Day 1, along with the on-demand BPAs (per investigator's discretion and within bleeding dosing guidelines) for treatment of breakthrough bleeding episodes, up to a total of 9 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of low tumour burden, CD20+ follicular lymphoma~* Ann Arbor Stage II, III or IV~Exclusion Criteria:~* Has receive rituximab~* Allergies or hypersensitivity to murine, chimeric, human or humanised proteins~* Previous treatment for NHL~* Any malignancy~* Current or recent treatment with any other investigational medicinal product or device~* pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P10 (Type: EXPERIMENTAL): CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
- Rituxan (Type: ACTIVE_COMPARATOR): Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe Hemophilia A patients~Exclusion Criteria:~-

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities (Type: EXPERIMENTAL): PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
- PK-guided EHL FVIII concentrates prophylaxis alone (Type: ACTIVE_COMPARATOR): PK-guided EHL FVIII concentrates prophylaxis alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary sclerosing cholangitis (PSC) established by all of the following criteria:~  * Alkaline phosphatase \>1.5x upper limit of normal for at least 6 months prior to study enrollment~ * Cholangiography demonstrating intrahepatic and/or extrahepatic biliary dilation, beading, and/or strictures consistent with PSC~ * Liver histology (if available for review) consistent with or diagnostic of PSC~* Women of child-bearing potential willing to use birth control for the duration of the study.~Exclusion Criteria:~* Treatment with any investigational agents within three months prior to or during the study~* Treatment with systemic antibiotics, azulfidine, systemic corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, tacrolimus, or vitamin E within three months prior to or during the study.~* Concomitant treatment with NSAIDS, antiplatelet agents, antihyperlipidemics, and anticoagulant warfarin.~* Anticipated need for liver transplant within one year as determined by Mayo PSC risk score (\<80% one-year survival without transplant)~* Active drug or alcohol use~* Findings suggestive of liver disease of an alternative or concomitant etiology, such as chronic alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis, or secondary sclerosing cholangitis (e.g., post-liver transplantation biliary stricture)~* Pregnancy or lactation~* Any condition that, in the opinion of the investigator, would interfere with the patient's ability to complete the study safely or successfully.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Curcumin (Type: EXPERIMENTAL): Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have written informed consent provided by legal parent, guardian, or authorized agent prior to participation in the study or study-only related procedures.~2. Be between birth (28 weeks to \< 40 weeks gestational age) to ≤ 16 years of age.~3. Have new (less than 7 days) onset of fever, documented by temperature greater than or equal to 101.0 ºF (38.3 ºC).~Exclusion Criteria:~1. Have inadequate intravenous access.~2. Have received antipyretic drug therapy within 2 hours before dosing.~3. Have any history of allergy or hypersensitivity to NSAIDs or aspirin.~4. Have received another investigational drug within the past 30 days.~5. Be otherwise unsuitable for the study, in the opinion of the Investigator.~6. Have a fever due to hyperthermia.~7. Pregnant or nursing.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- ibuprofen (Type: EXPERIMENTAL): Ibuprofen, 10 mg/kg
- Acetaminophen (Type: ACTIVE_COMPARATOR): Acetaminophen, 10mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete